These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 27995466)

  • 21. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
    Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
    Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
    Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
    Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate.
    Yousaf AM; Mustapha O; Kim DW; Kim DS; Kim KS; Jin SG; Yong CS; Youn YS; Oh YK; Kim JO; Choi HG
    Int J Nanomedicine; 2016; 11():213-21. PubMed ID: 26834471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.
    Liu P; Zhou JY; Chang JH; Liu XG; Xue HF; Wang RX; Li ZS; Li CS; Wang J; Liu CZ
    Drug Des Devel Ther; 2020; 14():2959-2975. PubMed ID: 32801637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.
    Miao X; Sun C; Jiang T; Zheng L; Wang T; Wang S
    J Pharm Pharm Sci; 2011; 14(2):196-214. PubMed ID: 21733409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
    Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
    Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperoside nanocrystals for HBV treatment: process optimization, in vitro and in vivo evaluation.
    Shen B; Wu N; Shen C; Zhang F; Wu Y; Xu P; Zhang L; Wu W; Lu Y; Han J; Wang Y; Yuan H
    Drug Dev Ind Pharm; 2016 Nov; 42(11):1772-81. PubMed ID: 27032257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent.
    Tran TH; Poudel BK; Marasini N; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Feb; 443(1-2):50-7. PubMed ID: 23318367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spironolactone nanocrystals for oral administration: Different pharmacokinetic performances induced by stabilizers.
    Mu S; Li M; Guo M; Yang W; Wang Y; Li J; Fu Q; He Z
    Colloids Surf B Biointerfaces; 2016 Nov; 147():73-80. PubMed ID: 27490456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, optimization and in vitro-in vivo evaluation of smart nanocaged carrier delivery of multifunctional PEG-chitosan stabilized silybin nanocrystals.
    Liu Y; Wang Y; Zhao J
    Int J Biol Macromol; 2019 Mar; 124():667-680. PubMed ID: 30502425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of ursolic acid-phospholipid complex by solvent-assisted grinding method to improve dissolution and oral bioavailability.
    Wang W; Zhang W; Jiang Y; Wang X; Zhang X; Liu H; Zhang T
    Pharm Dev Technol; 2020 Jan; 25(1):68-75. PubMed ID: 31544585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro/in vivo evaluation of felodipine micropowders prepared by the wet-milling process combined with different solidification methods.
    Meng J; Li S; Yao Q; Zhang L; Weng Y; Cai C; Xu H; Tang X
    Drug Dev Ind Pharm; 2014 Jul; 40(7):929-36. PubMed ID: 23614872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies.
    Fu Q; Sun J; Zhang D; Li M; Wang Y; Ling G; Liu X; Sun Y; Sui X; Luo C; Sun L; Han X; Lian H; Zhu M; Wang S; He Z
    Colloids Surf B Biointerfaces; 2013 Sep; 109():161-6. PubMed ID: 23668980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral fast-dissolving films containing lutein nanocrystals for improved bioavailability: formulation development, in vitro and in vivo evaluation.
    Liu C; Chang D; Zhang X; Sui H; Kong Y; Zhu R; Wang W
    AAPS PharmSciTech; 2017 Nov; 18(8):2957-2964. PubMed ID: 28462465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baicalin-berberine complex nanocrystals orally promote the co-absorption of two components.
    Li Z; Liu Y; Wang J; Feng X; Nwafor EO; Zhang Y; Liu R; Dang W; Zhang Q; Yu C; Pi J; Liu Z
    Drug Deliv Transl Res; 2022 Dec; 12(12):3017-3028. PubMed ID: 35476182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation.
    Yousaf AM; Kim DW; Oh YK; Yong CS; Kim JO; Choi HG
    Int J Nanomedicine; 2015; 10():1819-30. PubMed ID: 25784807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation.
    Chen L; Wang Y; Zhang J; Hao L; Guo H; Lou H; Zhang D
    Eur J Pharm Biopharm; 2014 May; 87(1):160-9. PubMed ID: 24333772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.